Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methoxyflurane inhalation - Medical Developments International

Drug Profile

Methoxyflurane inhalation - Medical Developments International

Alternative Names: Anecotan; Green whistle; ME-MEOTH; Methofane; Methoflurane; Methofluranum; Methoxane; Methoxyfluran; Metofane; Metoxifluran; NSC-110432; Penthrane; Penthrop; Penthrox; PENTHROX; Penthrox-3; Pentran; Pentrane

Latest Information Update: 13 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medical Developments International
  • Developer LINK Healthcare; Medical Developments International; Mundipharma International; Purdue Pharma
  • Class Analgesics; Fluorinated hydrocarbons; General anaesthetics; Methyl ethers; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action GABA receptor modulators; Gap junction modulators; Glutamate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 06 Dec 2019 Russian Ministry of Health accepts Marketing Authorisation Application for methoxyflurane inhalation for Pain for review
  • 21 Nov 2019 Preclinical trials in Pain in China (Inhalation) before November 2019
  • 21 Nov 2019 Chinese National Medical Product Administration (NMPA) approves the IND application for methoxyflurane inhalation in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top